AsedaSciences® helps chemists design safer compounds by providing actionable, biologically relevant predictions of the potential of human and environmental safety risk at the very start of the R&D process, without the use of animals.
We achieve this by providing compound profiling services that integrate novel multi-parametric phenotypic screens and proprietary machine learning algorithms to analyze, compare and predict the potential safety risk of a new target compound.
Earlier identification of potential toxicity delivers the greatest financial benefits for the chemical producing industries by reducing the massive costs of downstream failures that occur at all phases of development.
Our compound screening and characterization services provide valuable information related to the potential risk of toxicity for any new compounds in early research and development - a powerful SAR tool at the early Hit-to-Lead and Lead Optimization phases to aid in Fail-Fast initiatives to improve compound prioritization and reduce the risk of costly, downstream failures .
Earlier identification of potential toxicity delivers the greatest financial benefits for the chemical producing industries by reducing the massive costs of downstream failures that occur at all phases of development. AsedaSciences can help predict the hidden safety risks and accelerate informed decision making on whether to Approve, Improve or Remove™ a compound from the R&D pipeline.
25-30% of potential therapeutic compounds entering Phase II and Phase III clinical trials fail due to patient safety concerns, ultimately costing the pharmaceutical industry billions of dollars. By predicting risk of compound toxicity at the start of Drug Discovery, chemists can design safer drugs that will assist in improving the quality of the drug discovery pipeline. This in turn will help reduce the financial burden of later stage failures, reduce and refine the use of animals and minimize the safety risk to patients